224 related articles for article (PubMed ID: 30848423)
1. Benefits of Beta-Blockade in Sepsis and Septic Shock: A Systematic Review.
Lee YR; Seth MS; Soney D; Dai H
Clin Drug Investig; 2019 May; 39(5):429-440. PubMed ID: 30848423
[TBL] [Abstract][Full Text] [Related]
2. Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial.
Unger M; Morelli A; Singer M; Radermacher P; Rehberg S; Trimmel H; Joannidis M; Heinz G; Cerny V; Dostál P; Siebers C; Guarracino F; Pratesi F; Biancofiore G; Girardis M; Kadlecova P; Bouvet O; Zörer M; Grohmann-Izay B; Krejcy K; Klade C; Krumpl G
Trials; 2018 Nov; 19(1):637. PubMed ID: 30454042
[TBL] [Abstract][Full Text] [Related]
3. Beta-blocker use in severe sepsis and septic shock: a systematic review.
Sanfilippo F; Santonocito C; Morelli A; Foex P
Curr Med Res Opin; 2015; 31(10):1817-25. PubMed ID: 26121122
[TBL] [Abstract][Full Text] [Related]
4. Benefits of combination therapy of hydrocortisone, ascorbic acid and thiamine in sepsis and septic shock: A systematic review.
Lee YR; Vo K; Varughese JT
Nutr Health; 2022 Mar; 28(1):77-93. PubMed ID: 34039089
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of β-adrenergic blockade therapy on septic shock and sepsis: A systematic review and meta-analysis of randomized controlled studies.
Li J; Sun W; Guo Y; Ren Y; Li Y; Yang Z
Cytokine; 2020 Feb; 126():154916. PubMed ID: 31756644
[TBL] [Abstract][Full Text] [Related]
6. [Beta-blockers in Septic Shock].
Uhlig C; Spieth PM
Anasthesiol Intensivmed Notfallmed Schmerzther; 2018 Nov; 53(11-12):787-792. PubMed ID: 30458576
[TBL] [Abstract][Full Text] [Related]
7. The influence of esmolol on septic shock and sepsis: A meta-analysis of randomized controlled studies.
Liu P; Wu Q; Tang Y; Zhou Z; Feng M
Am J Emerg Med; 2018 Mar; 36(3):470-474. PubMed ID: 29269160
[TBL] [Abstract][Full Text] [Related]
8. Sepsis and beta-blockade: a look into diastolic function.
Astuto M
Curr Med Res Opin; 2015; 31(10):1827-8. PubMed ID: 26211819
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic response to β-blockers in severe sepsis and septic shock: A review of current literature.
van Loon LM; van der Hoeven JG; Lemson J
J Crit Care; 2019 Apr; 50():138-143. PubMed ID: 30540967
[TBL] [Abstract][Full Text] [Related]
10. Effect of Ultrashort-Acting β-Blockers on Mortality in Patients With Sepsis With Persistent Tachycardia Despite Initial Resuscitation: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Hasegawa D; Sato R; Prasitlumkum N; Nishida K; Takahashi K; Yatabe T; Nishida O
Chest; 2021 Jun; 159(6):2289-2300. PubMed ID: 33434497
[TBL] [Abstract][Full Text] [Related]
11. A new frontier for an old drug? A word of caution for beta-blockers in sepsis!
Maybauer MO; Maybauer DM
Curr Med Res Opin; 2015; 31(10):1829-30. PubMed ID: 26296157
[TBL] [Abstract][Full Text] [Related]
12. Effects of Chronic Antihypertensives on Vasopressor Dosing in Septic Shock.
DeMott JM; Patel G; Lat I
Ann Pharmacother; 2018 Jan; 52(1):40-47. PubMed ID: 28799416
[TBL] [Abstract][Full Text] [Related]
13. Beta-blockers in septic shock: a review.
Vela-Vásquez RS; Grigorov-Tzenkov I; Aguilar JL
Rev Esp Anestesiol Reanim; 2015 Feb; 62(2):90-5. PubMed ID: 25152109
[TBL] [Abstract][Full Text] [Related]
14. Benefits of esmolol in adults with sepsis and septic shock: An updated meta-analysis of randomized controlled trials.
Zhang J; Chen C; Liu Y; Yang Y; Yang X; Yang J
Medicine (Baltimore); 2022 Jul; 101(27):e29820. PubMed ID: 35801730
[TBL] [Abstract][Full Text] [Related]
15. Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials.
Chang W; Xie JF; Xu JY; Yang Y
BMJ Open; 2018 Mar; 8(3):e019338. PubMed ID: 29602841
[TBL] [Abstract][Full Text] [Related]
16. Effects of low doses of esmolol on cardiac and vascular function in experimental septic shock.
Wei C; Louis H; Schmitt M; Albuisson E; Orlowski S; Levy B; Kimmoun A
Crit Care; 2016 Dec; 20(1):407. PubMed ID: 27998289
[TBL] [Abstract][Full Text] [Related]
17. Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days.
Fuchs C; Wauschkuhn S; Scheer C; Vollmer M; Meissner K; Kuhn SO; Hahnenkamp K; Morelli A; Gründling M; Rehberg S
Br J Anaesth; 2017 Oct; 119(4):616-625. PubMed ID: 29121280
[TBL] [Abstract][Full Text] [Related]
18. Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing non-cardiac surgery.
Blessberger H; Lewis SR; Pritchard MW; Fawcett LJ; Domanovits H; Schlager O; Wildner B; Kammler J; Steinwender C
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD013438. PubMed ID: 31556094
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis.
Zarychanski R; Abou-Setta AM; Kanji S; Turgeon AF; Kumar A; Houston DS; Rimmer E; Houston BL; McIntyre L; Fox-Robichaud AE; Hébert P; Cook DJ; Fergusson DA;
Crit Care Med; 2015 Mar; 43(3):511-8. PubMed ID: 25493972
[TBL] [Abstract][Full Text] [Related]
20. Recent Updates in the Pharmacological Management of Sepsis and Septic Shock: A Systematic Review Focused on Fluid Resuscitation, Vasopressors, and Corticosteroids.
Allen JM; Feild C; Shoulders BR; Voils SA
Ann Pharmacother; 2019 Apr; 53(4):385-395. PubMed ID: 30404539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
